Last reviewed · How we verify

Moxifloxacin (Topical)

University of California, San Francisco · FDA-approved active Small molecule

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms. Used for Bacterial conjunctivitis, Bacterial corneal ulcer, Post-operative ocular infection prophylaxis.

At a glance

Generic nameMoxifloxacin (Topical)
SponsorUniversity of California, San Francisco
Drug classFluoroquinolone antibiotic
TargetBacterial DNA gyrase and topoisomerase IV
ModalitySmall molecule
Therapeutic areaInfectious Disease / Ophthalmology
PhaseFDA-approved

Mechanism of action

As a broad-spectrum fluoroquinolone, moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA unwinding and replication. This dual inhibition leads to rapid bactericidal activity against a wide range of gram-positive and gram-negative bacteria, as well as atypical organisms. When applied topically to the eye, it achieves high local concentrations to treat ocular infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: